抄録
Background/Aim: The cytolytic activity (CYT) score is a new index of cancer immunity calculated from the mRNA expression levels of GZMA and PRF1. We assessed the clinical significance of the CYT score in HCC. Materials and Methods: The calculated CYT scores of peripheral blood cells (GSE24759), cell lines (CCLE) and HCC tissues (TCGA, GSE14520 and Kyushu cohorts) were assessed. Then, immunohistochemical analysis (IHC) of GZMA and PRF1 was performed. Results: The CYT scores of HCC tissues were lower than those of non-cancerous tissues. The 5-year recurrence-free survival of patients with low CYT scores was significantly shorter than that of patients with high CYT scores. Multivariate analysis indicated that the CYT score was an independent prognostic factor for RFS in TCGA and GSE14520 cohorts. Conclusion: CYT score could be a useful prognostic biomarker in HCC, possibly through reflecting the host immune status.
| 本文言語 | 英語 |
|---|---|
| ページ（範囲） | 6631-6638 |
| ページ数 | 8 |
| ジャーナル | Anticancer research |
| 巻 | 38 |
| 号 | 12 |
| DOI | |
| 出版ステータス | 出版済み - 12月 2018 |
!!!All Science Journal Classification (ASJC) codes
- 腫瘍学
- 癌研究
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
